Rtw Investments, LP Immunic, Inc. Transaction History

Rtw Investments, LP

$6.51 Billion
Q2 2025

A detailed history of Rtw Investments, LP transactions in Immunic, Inc. stock. As of the latest transaction made, Rtw Investments, LP holds 402,107 shares of IMUX stock, worth $341,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares

402,107

Holding current value

$341,790

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.66 - $1.15 $265,390 - $462,423	402,107 New	402,107 $281,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $265,006 - $355,666	232,462 Added 5.36%	4,567,717 $6.03 Million
Q3 2023 Nov 14, 2023	BUY	$1.35 - $2.87 $55,074 - $117,084	40,796 Added 0.95%	4,335,255 $6.37 Million
Q1 2023 May 15, 2023	BUY	$1.35 - $2.87 $584,778 - $1.24 Million	433,169 Added 11.22%	4,294,459 $6.4 Million
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $1.24 Million - $11.9 Million	1,099,322 Added 39.8%	3,861,290 $5.41 Million
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $176,704 - $691,573	56,455 Added 2.09%	2,761,968 $9.58 Million
Q1 2022 May 16, 2022	BUY	$9.54 - $14.26 $9.45 Million - $14.1 Million	990,043 Added 57.71%	2,705,513 $30.6 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $2.53 Million - $3.53 Million	344,656 Added 25.14%	1,715,470 $16.4 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $3.62 Million - $5.98 Million	450,000 Added 48.87%	1,370,814 $12.1 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $123,106 - $169,437	8,318 Added 0.91%	920,814 $14.1 Million
Q3 2020 Nov 16, 2020	BUY	$11.74 - $22.0 $10.7 Million - $20.1 Million	912,496 New	912,496 $16.9 Million

Others Institutions Holding IMUX

# of Institutions

Shares Held

50M

Call Options Held

13.2K

Put Options Held

60.6K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $26M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.

Account